SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Affimed N.V. (AFMD) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+4032.2%).
- Analyst consensus target $7.50 (+4032.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 43/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AFMD
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.33
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-7.09
Book Value / Share$0.00
Revenue / Share$0.55
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$7.50 (+4032.2%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$-0.10 |
$3.38M |
$-259K |
-7.7% |
| 2015 |
$-7.10 |
$7.56M |
$-20.24M |
-267.6% |
| 2016 |
$-9.70 |
$6.31M |
$-32.22M |
-510.2% |
| 2017 |
$-6.91 |
$2.01M |
$-30.22M |
-1503.6% |
| 2018 |
$-3.22 |
$23.74M |
$-19.48M |
-82.1% |
| 2019 |
$-5.04 |
$21.39M |
$-32.37M |
-151.3% |
| 2020 |
$-4.96 |
$28.36M |
$-41.37M |
-145.9% |
| 2021 |
$-4.81 |
$40.37M |
$-57.52M |
-142.5% |
| 2022 |
$-6.04 |
$41.35M |
$-86M |
-208% |
| 2023 |
$-7.09 |
$8.28M |
$-105.94M |
-1280.2% |
